- Lobbying
- Lobbying by Sorrento Therapeutics, Inc.
Lobbying Relationship
Bills mentioned
S.1895: Lower Health Care Costs Act
Sponsor: Lamar Alexander (R-Tenn.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Mimi Simoneaux Kneuer | Legislative Assistant, Legislative Director, Chief of Staff, Rep. Tauzin |
Thomas Tauzin | n/a |
Michael Meirovitz | n/a |
Roger Adams | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q2 Report
Lobbying Issues
Agencies Lobbied
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
Food & Drug Administration (FDA)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medicare
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medicare
Amendment
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medicare
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medicare
Registration
Issue(s) they said they’d lobby about: Drug reimbursement and pricing; non-opioid pain management policies and regulations, and other issues related to health policy..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate